Regencell Bioscience Holdings (RGC) Long-Term Deferred Tax (2020 - 2021)
Regencell Bioscience Holdings' (RGC) quarterly Long-Term Deferred Tax came in at $659669.0 in Q2 2021, up 50.8% YoY from $437456.0 in Q2 2020, and up 50.8% on a QoQ basis from $437456.0 in Q2 2020.
Regencell Bioscience Holdings (RGC) Long-Term Deferred Tax (2020 - 2021) Analysis & Trends
Regencell Bioscience Holdings (RGC) has 2 years of Long-Term Deferred Tax data on file, last reported at $659669.0 in Q2 2021.
- Quarterly Long-Term Deferred Tax rose 50.8% year-over-year to $659669.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $659669.0 (up 50.8% YoY) and the FY2021 annual result came in at $659669.0, up 50.8% from the prior year.
- Long-Term Deferred Tax grew to $659669.0 in Q2 2021, from $437456.0 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $659669.0 in Q2 2021 to a low of $437456.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Regencell Bioscience Holdings | 2.61 Bn | 2.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 659,669.00 |
| Jun 30, 2020 | 437,456.00 |